Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the successful enrollment of 654 participants in the INTEGUMENT-1 Phase 3 trial for roflumilast cream, aimed at treating atopic dermatitis (AD) in adults and children. The trial continues with INTEGUMENT-2, with topline data expected by the end of 2022. If trials prove successful, the company anticipates filing for a supplemental New Drug Application in 2023. Atopic dermatitis affects around 26 million individuals in the U.S., underlying the significance of this potential treatment.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the grant of 22,200 restricted stock units and options to purchase 44,500 shares to five new employees. These awards are part of the 2022 Inducement Plan and were approved by the Compensation Committee. Restricted stock units vest over four years, while stock options have a ten-year term with an exercise price of $22.25 per share, reflecting the stock's closing price on the grant date, July 27, 2022. This initiative aligns with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced a public offering of 7,500,000 shares at $20.00 per share, with expected proceeds of $150 million. The offering also includes a 30-day option for underwriters to purchase an additional 1,125,000 shares. Proceeds will fund the development and commercialization of its programs, including ZORYVE, along with general corporate purposes. The offering is set to close on August 5, 2022, and follows an effective shelf registration statement filed on February 1, 2021.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the commencement of an underwritten public offering of $150 million of its common stock, with all shares sold by the company. This offering is subject to market conditions, and there is no guarantee regarding its completion or terms. Furthermore, Arcutis plans to give underwriters a 30-day option to purchase an additional 15% of the shares. The offering will be made pursuant to an effective shelf registration statement filed with the SEC. Morgan Stanley, Cowen, and Guggenheim Securities will act as bookrunning managers.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced FDA approval for ZORYVE (roflumilast) cream 0.3%, targeting plaque psoriasis treatment in patients aged 12 and older. This approval is significant as it addresses the needs of patients with immune-mediated dermatological conditions. The company aims to leverage its innovative development platform, focusing on unmet patient needs in dermatology. A conference call will discuss the FDA approval details and future plans for commercialization, highlighting Arcutis's commitment to advancing dermatological therapies.
Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) cream 0.3%, the first topical PDE4 inhibitor for treating plaque psoriasis in patients 12 and older. ZORYVE offers effective plaque clearance and itch reduction, suitable for all severities without duration limitations. The steroid-free cream is expected to launch by mid-August, supported by a $125 million funding draw from SLR Capital Partners. The innovative HydroARQ Technology enhances patient experience, focusing on simplifying treatment for this widespread skin condition.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced that Health Canada has accepted its New Drug Submission (NDS) for roflumilast cream 0.3% to treat plaque psoriasis in adults and adolescents. This cream, if approved by the target action date of April 30, 2023, will be the first topical PDE4 inhibitor available in Canada. The submission is supported by positive results from Phase 3 DERMIS-1 and DERMIS-2 trials, where roflumilast demonstrated significant efficacy over a vehicle treatment. Arcutis is also establishing Canadian operations to support market entry.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has approved the grant of 7,500 restricted stock units and options for 16,500 shares to three new employees as part of their 2022 Inducement Plan. These grants were made to incentivize new hires and are in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units and stock options will vest over four years, contingent on continued employment. The options have an exercise price of $21.73, reflecting the market price on the grant date of July 1, 2022. This initiative is aimed at fostering talent to support Arcutis’ commitment to innovation in immuno-dermatology.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported positive topline results from its pivotal Phase 3 STRATUM trial for roflumilast foam, a topical treatment for moderate to severe seborrheic dermatitis. The study achieved its primary endpoint, with 80.1% of patients showing IGA success at week eight, significantly higher than the 59.2% in the vehicle group (P0.0001). Over 50% of patients achieved clear skin by week eight, and roflumilast foam exhibited a favorable safety profile. An NDA submission is anticipated in the first half of 2023.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 24,000 restricted stock units and options for 64,900 shares to seven newly hired employees on June 1, 2022. This was approved by the Compensation Committee under the 2022 Inducement Plan. Restricted stock units vest over four years, with 25% vesting annually. The options also vest over four years, with a one-year cliff and subsequent monthly vesting, and have an exercise price of $20.29. This action aligns with Nasdaq Listing Rule 5635(c)(4).